
Reviews and Background

The Insulin-Like Growth Factors

1. Rosenfeld RG and Roberts CT (eds.) 1999. The IGF system. molecularbiology, physiology, and clinical applications. Totowa, NJ: Humana Press.
2. LeRoith D, Zumkeller W, and Baxter RC. (eds.) 2003. Insulin-like growth factors. New York : Kluwer Academic/Plenum Publishers.
3. International Symposium on Insulin-like Growth Factors (4th) (1998): Tokyo, Japan. Amsterdam, New York: Elsevier.
4. Muller EE (ed.) 1998. IGFs in the nervous system. Milano; New York; Springer.
5. Simpson HL, Umpleby AM, and Russell-Jones DL. Insulin-like growth factor-I and diabetes. A review. Growth Horm IGF Res 1998;8:83–95.
6. Baxter RC. Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am J Physiol Endocrinol Metab 2000;278:E967–E976.
7. Jones JI and Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16:3–34.
8. Rajaram S, Baylink DJ, and Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 1997;18:801–831.
9. Rosenbloom AL. IGF-I treatment of diabetes. Pediatr Diabetes 2001;2:123–130.
10. LeRoith D and Roberts CT, Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003;195:127–137.
11. LeRoith D and Helman L. The new kid on the block(ade) of the IGF-1 receptor. Cancer Cell 2004;5:201–202.
12. Holly JM, Perks CM, and Stewart CE. Overview of insulin-like growth factor physiology. Growth Horm IGF Res 2000;10 Suppl A:S8–S9.
13. Thissen JP, Ketelslegers, JM, and Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev 1994;15:80–101.
14. Le Roith, D, Bondy C, Yakar S, Liu J, and Butler A. The somatomedin hypothesis: 2001 Endocr. Rev 2001;22: 53–74.
15. Jerome L, Shiry L, Leyland-Jones B. Anti-insulin-like growth factor strategies in breast cancer. Seminars in Oncology 2004;31:54–63.
16. Daughaday WH, Hall KI, Raben MS, Salmon WD, Jr., Van Den Brande J., and Van Wyk JJ. Somatomedin: proposed designation for sulphation factor. Nature 1972;235:107.
17. Salmon WD, Jr. and Daughaday WH. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med 1957;49:825–836.

From: *IGF and Nutrition in Health and Disease*

Edited by: M. S. Houston, J. M. P. Holly, and E. L. Feldman © Humana Press Inc., Totowa, NJ

Related Professional Organizations and Journals

PROFESSIONAL SOCIETIES AND ORGANIZATIONS

http://www.igf-society.org/h/join_igfs.html

With close to 1000 members from dozens of countries, the **International Society for IGF Research** is a unique organization devoted to basic and applied research on a network of molecules called insulin-like growth factors (IGFs), their receptors, and their binding proteins (IGFBPs). Together, these scientists, educators, clinicians, and students who make up the organization's membership represent the spectrum of interests in IGF research from molecular biology to clinical applications. Since its inception, the IGF Society has worked to promote excellence and interest in research and education on the role of these molecules in the etiology, pathogenesis, and treatment of diseases such as cancer, diabetes, growth disorders, heart disease, and neurological illnesses.

<http://www.asns.org/>

The American Society for Nutritional Sciences (3500+ members) is the premier research society dedicated to improving the quality of life through the science of nutrition. The society fulfills its mission by: fostering and enhancing research in animal and human nutrition; providing opportunities for sharing, disseminating, and archiving peer-reviewed nutrition research results (at its annual meeting and in its official publication, the *Journal of Nutrition*); fostering quality education and training in nutrition; upholding standards for ethical behavior in research, the protection of human subjects, and the care and treatment of research animals; providing opportunities for fellowship and support among nutritionists; and bringing scientific knowledge to bear on nutrition issues through communication and influence in the public domain. The clinical division is the **American Society of Clinical Nutrition** (<http://www.ascn.org/>). The official publication is *The American Journal of Clinical Nutrition*, which focuses on basic and clinical studies relevant to human nutrition.

<http://www.endo-society.org/>

The Endocrine Society is the world's largest and most active professional organization of endocrinologists in the world. Founded in 1916, the society is internationally

From: *IGF, Nutrition, and Health*

Edited by: S. M. Houston, J. M. P. Holly, and E. L. Feldman © Humana Press Inc., Totowa, NJ

known as the leading source of state-of-the-art research and clinical advancements in endocrinology and metabolism. The Endocrine Society is dedicated to promoting excellence in research, education, and clinical practice in the field of endocrinology. The Endocrine Society is an international body with more than 11,000 members from more than 80 countries. The diverse membership represents medicine, molecular and cellular biology, biochemistry, physiology, genetics, immunology, education, industry, and allied health.

<http://www.clinnutr.org/>

The American Society for Parenteral and Enteral Nutrition promotes professional communication among and within professional disciplines in the broad field of clinical nutrition including parenteral and enteral nutrition through national and regional meetings, local seminars, scientific, and clinical and educational exhibits and publications. The society promotes proper application of clinical and research experience to the practice of nutritionally sound medicine.

<http://www.nih.gov>

Founded in 1887, the **National Institutes of Health (NIH)** today is one of the world's foremost medical research centers, and the Federal focal point for medical research in the United States. The NIH, comprising 27 separate institutes and centers, is one of eight health agencies of the Public Health Service which, in turn, is part of the US Department of Health and Human Services. Simply described, the goal of NIH research is to acquire new knowledge to help prevent, detect, diagnose, and treat disease and disability from the rarest genetic disorder to the common cold. NIH works toward that mission by: conducting research in its own laboratories; supporting the research of non-federal scientists in universities, medical schools, hospitals, and research institutions throughout the country and abroad; helping in the training of research investigators; and fostering communication of medical and health sciences information.

<http://www.nsf.gov/>

The National Science Foundation (NSF) is an independent agency of the US Government, established by the National Science Foundation Act of 1950. NSF's mission is to promote the progress of science, to advance the national health, prosperity, and welfare, and to secure the national defense.

<http://www.ilsa.org/>

Founded in 1978, the **International Life Sciences Institute (ILSI)** is a nonprofit, worldwide foundation that seeks to improve the well-being of the general public through the pursuit of balanced science. Its goal is to further the understanding of scientific issues relating to nutrition, food safety, toxicology, risk assessment, and the environment by bringing together scientists from academia, government, and industry.

<http://www.eatright.org/>

The American Dietetic Association is the largest group of food and nutrition professionals in the United States, members are primarily registered dietitians and dietetic technicians, registered. Programs and services include promoting nutrition information for the public; sponsoring national events, media and marketing programs, and publications (*The Journal of the American Dietetic Association*), and lobbying for federal legislation. Also available through the web site are member services, nutrition resources, news, classifieds, and government affairs. Assistance in finding a dietitian, marketplace news, and links to related sites also can be found.

<http://www.faseb.org>

The **Federation of American Societies for Experimental Biology** (FASEB) is a coalition of member societies with the purpose of enhancing the profession of biomedical and life scientists, emphasizing public policy issues. FASEB offers logistical and operational support as well as sponsoring scientific conferences and publications (*The FASEB Journal*).

<http://www.usda.gov>

The **United States Department of Agriculture** (USDA) provides a broad scope of service to the nation's farmers and ranchers. In addition, the USDA ensures open markets for agricultural products, food safety, environmental protection, conservation of forests and rural land, and the research of human nutrition. The Food and Nutrition Service administers the USDA's 15 food assistance programs for children and needy families with the mission to reduce hunger and food insecurity. <http://www.fns.usda.gov/fns/>

<http://www.who.int/nut/>

The **World Health Organization** has regarded nutrition to be of fundamental importance for overall health and sustainable development. The global priority of nutritional issues, activities, mandates, resources, and research are presented in detail.

<http://www.diabetes.org>

American Diabetes Association

<http://www.aace.com>

American Society of Clinical Endocrinologists

<http://www.amcollnutr.org/>

American College of Nutrition

<http://www.asbmr.org/>

American Society for Bone and Mineral Research

<http://www.jdf.org>

Juvenile Diabetes Research Foundation

<http://www.nmss.org>

National Multiple Sclerosis Society

<http://www.neuropathy.org>

The Neuropathy Association

<http://www.asas.org/>

American Society of Animal Science

<http://www.bsped.org.uk>

British Society for Paediatric Endocrinology and Diabetes

<http://www.hgfound.org/>

Human Growth Foundation

<http://www.ghresearchsociety.org/bin/Default.asp>

Growth Hormone Research Society

<http://www.endocrinology.org/default.htm>

Society for Endocrinology

<http://www.the-aps.org/about/index.htm>

American Physiological Society

<http://www.aacr.org/>

American Association of Cancer Research

<http://www.asbmb.org/ASBMB/>

American Society for Biochemistry and Molecular Biology

<http://www.ascb.org/>

American Society for Cell Biology

<http://www.ama-assn.org/>

American Medical Association

<http://www.ibmsonline.org/>

International Bone and Mineral Society

<http://www.nof.org/>

National Osteoporosis Foundation

JOURNALS

<http://www.harcourt-international.com/journals/ghir/>

Growth Hormone and IGF Research

<http://www.nutrition.org/>

Journal of Nutrition

<http://www.ajcn.org/>

American Journal of Clinical Nutrition

<http://jcem.endojournals.org/>

Journal of Endocrinology and Metabolism

<http://endo.endojournals.org/>

Endocrinology

<http://mend.endojournals.org/>

Molecular Endocrinology

<http://journals.endocrinology.org/JME/jme.htm>

Journal of Molecular Endocrinology

<http://edrv.endojournals.org/>

Endocrine Reviews

<http://www.blackwellpublishing.com/>

Clinical Endocrinology

<http://journals.endocrinology.org/JOE/joe.htm>

Journal of Endocrinology

<http://www.elsevier.com/>

Trends in Endocrinology and Metabolism

<http://www.the-aps.org/publications/ajpendo/index.htm>

American Journal of Physiology – Endocrinology and Metabolism

<http://www.the-aps.org/publications/ajpendo/index.htm>

American Journal of Physiology – Cell Physiology

<http://rphr.endojournals.org/>

Recent Progress in Hormone Research

<http://www.sciencemag.org/>

Science

<http://www.nature.com/>

Nature

<http://www.cellpress.com/>

*Cell; Molecular Cell; Neuron; Cancer Cell; Immunity
Chemistry and Biology; Developmental Cell*

<http://annurev.org/>

Annual Review of Nutrition

<http://www.ilsa.org/>

Nutrition Reviews

<http://www.clinnutr.org>

Journal of Parenteral and Enteral Nutrition

<http://www.nature.com/ejcn>

European Journal of Clinical Nutrition

<http://www.eatright.org/journaltoc.html>

Journal of the American Dietetic Association

<http://www.ingenta.com/journals/browse/els/09552863>

Journal of Nutritional Biochemistry

<http://www.thieme.com/SID1990087552676/journals/pubid-388413336.html>

Hormone and Metabolic Research

<http://www.jbc.org/>

Journal of Biological Chemistry

<http://bmj.bmjournals.com/>

British Medical Journal

<http://embojournal.npgjournals.com/>

EMBO Journal

<http://www.pnas.org/>

Proceeding of the National Academy of Sciences

<http://content.nejm.org/>
New England Journal of Medicine

<http://bmj.bmjournals.com/>
British Medical Journal

<http://www.aacc.org/ccj/>
Clinical Chemistry

<http://www.currentopinion.com/>
Current Opinion Series

<http://www.elsevier.com/>
Cytokine and Growth Factor Reviews

<http://www.cabi-publishing.org/Journals.asp?SubjectArea=&PID=63>
British Journal of Nutrition

<http://journals.endocrinology.org/ERC/erc.htm>
Endocrine Related Cancer

<http://jas.fass.org/>
Journal of Animal Science

<http://www.thelancet.com/>
The Lancet

<http://www.annals.org/>
Annals of Internal Medicine

<http://diabetes.diabetesjournals.org>
Diabetes

<http://www.harcourt-international.com/journals/cale>
Cancer Letters

<http://www.jci.org>
Journal of Clinical Investigation

<http://www.jbc.org>
Journal of Biological Chemistry

<http://cancerres.aacrjournals.org>

Cancer Research

<http://content.karger.com>

Hormone Research

<http://www.elsevier.com>

Biochemical Biophysical Research Communications

Index

A

- AD, *see* Alzheimer's disease
- Aging, insulin-like growth factor axis
 - disease effects
 - cardiovascular disease, 165
 - dementia, 164
 - diabetes, 164, 165
 - immunodeficiency, 165
 - muscle wasting, 164
 - osteoporosis, *see* Osteoporosis
 - expression levels, 158–160
 - hormonal regulation, 160
 - longevity relationship
 - animal models, 165, 166
 - caloric restriction, 166
 - overview, 165
 - primate studies, 166
 - nutritional regulation, 161–164
 - physiology, 158
 - prospects for study, 168, 169
- Alcohol, muscle protein metabolism effects, 200, 201
- ALS, *see* Amyotrophic lateral sclerosis
- Alzheimer's disease (AD)
 - impact on insulin-like growth factor system, 212
 - insulin-like growth factor-I therapy, 212, 213
 - pathophysiology, 212
- Ames mouse, longevity, 166
- Amino acids
 - nutritional regulation of insulin-like growth factor-I expression, 33, 34
 - requirements in critical illness, 59, 60
- Amyotrophic lateral sclerosis (ALS)
 - impact on insulin-like growth factor system, 216, 217
 - insulin-like growth factor-I therapy, 217
 - pathophysiology, 216
- Angiotensin II
 - cardiac hypertrophy role, 312, 313
 - cardiomyocyte apoptosis mechanisms, 314
 - crosstalk with insulin-like growth factor-I signaling, 320, 321
- Anorexia nervosa
 - bone loss role of protein malnutrition, 183, 184
 - insulin-like growth factor-I in nutritional status assessment, 88, 89

Apoptosis

- cardiomyocyte apoptosis mechanisms
 - in heart failure
 - angiotensin II, 314
 - insulin-like growth factor-I, 315, 316
- insulin-like growth factor-I inhibition
 - in cancer, 338
- Ataxia telangiectasia, impact on insulin-like growth factor system, 214

B

- Bone growth, protein intake relationship, 184–188
- Bone mineral density, *see* Osteoporosis
- BPD, *see* Bronchopulmonary dysplasia
- Breast cancer, *see* Cancer
- Breast milk
 - insulin-like growth factor system components, 136, 140
 - mitogenic activity, 140
- Bronchopulmonary dysplasia (BPD), insulin-like growth factor axis defects, 139

C

- Caloric restriction, longevity effects, 166
- cAMP, *see* Cyclic AMP
- Cancer
 - breast cancer expression of insulin-like growth factor system proteins, 128
 - genetics, 331
 - height and cancer risk, 335
 - insulin-like growth factor binding proteins
 - expression, 332, 333
 - protease expression, 333, 334
 - insulin-like growth factor-I expression
 - circulating levels, 334, 335
 - mechanisms
 - apoptosis inhibition, 338
 - mitogenic effects, 337, 338
 - nutrition effects, 335–337
 - tumors, 332
 - insulin-like growth factor-I receptor expression, 125–127, 332
 - insulin-like growth factor-II expression, 126, 128, 332
 - prospects for study, 128, 129

- prostate cancer
 - insulin-like growth factor-I expression, 127, 128
 - insulin-like growth factor-II expression, 128
- Cardiovascular disease, insulin-like growth factor axis defects in aging, 165
- Cerebral hypoxic/ischemic injury
 - insulin-like growth factor-I therapy, 216
 - pathophysiology, 215, 216
- CF, *see* Cystic fibrosis
- Colon, *see* Intestine
- Congestive heart failure, *see* Heart failure
- Critical illness
 - anabolic hormone therapy, 63, 64
 - catabolism, 292
 - cytokine effects
 - anabolic hormone actions, 56–58
 - protein metabolism, 54–56
 - definition, 291, 292
 - insulin-like growth factor system
 - changes in acute phase, 293–295
 - changes in chronic phase, 295–297
 - growth hormone-releasing factors, effects in chronic phase, 298–301
 - insulin-like growth factor-I
 - muscle metabolism role, *see* Muscle protein metabolism
 - nutritional status assessment, 87, 88
 - pathophysiology of chronic changes, 297, 298
 - thyroid and gonadal axes interactions, 301, 303, 304
 - nutritional management
 - antioxidants, 64, 65
 - energy requirements, 60, 61
 - lipid metabolism and requirements, 61–63
 - micronutrients, 64, 65
 - overview, 58
 - prospects for study, 66
 - protein metabolism and requirements, 58–60
- Crohn's disease, *see* Inflammatory bowel disease
- Cyclic AMP (cAMP), regulation of insulin-like growth factor-I expression, 5
- Cystic fibrosis (CF), insulin-like growth factor-I in nutritional status assessment, 90
- D**
- Dementia, insulin-like growth factor axis defects in aging, 164
- Dexamethasone, insulin-like growth factor axis effects, 140
- Diabetes
 - insulin-like growth factor system
 - defects in aging, 164, 165
 - glucose homeostasis role, 252–254
 - insulin-like growth factor binding protein-1 levels, 259, 260
 - prospects for study, 262, 263
 - type I diabetes, 257, 258
 - type II diabetes, 258, 259
 - insulin-like growth factor-I therapy
 - side effects, 261, 262
 - type I diabetes, 261
 - type II diabetes, 261
 - nephropathy and insulin-like growth factor system, 236, 237, 259
 - neuropathy
 - impact on insulin-like growth factor system, 217, 218
 - insulin-like growth factor-I therapy, 218
 - pathophysiology, 217
 - retinopathy and insulin-like growth factor system, 259
- DNA microarray, differentiation of insulin versus insulin-like growth factor-I gene upregulation, 13, 14
- E**
- Elderly, *see* Aging
- F**
- Fasting
 - insulin-like growth factor-I expression effects, 26, 27, 35, 81
 - insulin-like growth factor-I sensitivity effects, 38, 39
- Fetal insulin-like growth factor axis, 134–136
- G**
- GH, *see* Growth hormone
- Glucocorticoids
 - muscle protein metabolism effects, 201, 202
 - nutritional regulation of secretion and insulin-like growth factor-I expression effects, 32, 33
- Glucose
 - insulin-like growth factor system in homeostasis, 252–254
 - nutritional regulation of insulin-like growth factor-I expression, 33, 34
- Growth hormone (GH)
 - binding protein, 29
 - cytokine effects on action, 57, 58
 - height and cancer risk, 335
 - inflammatory bowel disease management, 284
 - nutritional regulation of secretion and insulin-like growth factor-I expression effects, 27–29

- regulation of insulin-like growth factor-I expression, 5, 6, 27–29
 - releasing factors in critical illness, effects in chronic phase, 298–301
 - therapy in critical illness, 63, 64
 - total parenteral nutrition studies, 280, 281
 - zinc effects, *see* Zinc
- Growth hormone receptor (GHR)
- nutritional regulation and insulin-like growth factor-I expression effects, 29, 30
 - signal transduction, 30, 31
- H**
- HD, *see* Huntington's disease
- Heart failure
- cachexia effects on insulin-like growth factor system, 318, 319
 - cardiac hypertrophy mechanisms
 - angiotensin II, 312, 313
 - insulin-like growth factor-I, 313, 314
 - cardiomyocyte apoptosis mechanisms
 - angiotensin II, 314
 - insulin-like growth factor-I, 315, 316
 - insulin-like growth factor-I
 - crosstalk with angiotensin II signaling, 320, 321
 - expression levels, 320
 - therapy
 - cardiomyocyte growth and survival effects, 317, 318
 - overview, 316, 317
- Huntington's disease (HD), insulin-like growth factor-I therapy prospects, 213, 214
- I**
- IGF-I, *see* Insulin-like growth factor-I
- IGF-IR, *see* Insulin-like growth factor-I receptor
- IGF-II, *see* Insulin-like growth factor-II
- IGFBPs, *see* Insulin-like growth factor binding proteins
- IL-1, *see* Interleukin-1
- IL-6, *see* Interleukin-6
- Immunodeficiency, insulin-like growth factor axis defects in aging, 165
- Infants
- insulin-like growth factor axis regulation, 138, 139
 - nutritional status assessment using insulin-like growth factor-I, 86
- Inflammatory bowel disease
- insulin-like growth factor-I in fibrosis and inflammation, 283, 284
 - treatment
 - growth hormone, 284
 - insulin-like growth factor-I, 284
- Insulin
- cytokine effects on action, 56, 57
 - nutritional regulation of secretion and insulin-like growth factor-I expression effects, 31
 - regulation of insulin-like growth factor-I expression
 - aging, 161
 - overview, 5
 - therapy in critical illness, 63
- Insulin-like growth factor-I (IGF-I)
- congenital deficiency, 136, 138
 - gene mutations, 125
 - gene polymorphisms, 141
 - splice variants and nutritional regulation, 34
- Insulin-like growth factor-I receptor (IGF-IR)
- gene mutations, 125
 - homologs in lower organisms, 14–16
 - hybrid receptors, 122, 123
 - insulin receptor binding, 11
 - ligands, 122
 - signal transduction, 8–10, 13–16
 - structure, 8, 9
 - tumor expression, 125–127, 332
- Insulin-like growth factor-II (IGF-II)
- developmental expression, 122
 - forms, 7
 - tumor expression, 126, 128, 332
- Insulin-like growth factor binding proteins (IGFBPs)
- aging effects on levels, 158–160
 - cytokine effects on levels, 58
 - functional overview, 11, 12, 35, 123, 134, 227, 228
 - illness effects in neonates, 141
 - muscle protein metabolism effects, 202–205
 - nutrition effects on expression and metabolism, 35–38, 81
 - nutritional status assessment prospects, 91, 92
 - tumor expression, 332, 333
 - types, 11, 12, 123
- Insulin receptor (IR)
- homologs in lower organisms, 14–16
 - hybrid receptors, 122, 123
 - insulin-like growth factor-I receptor binding, 11
 - isoforms, 11, 122
 - pp120 modulation, 12, 13
 - signal transduction, 13–16
- Insulin resistance, *see also* Diabetes
- insulin-like growth factor-I therapy, 261
 - insulin-like growth factor system
 - changes, 255
 - glucose homeostasis role, 252–254
 - insulin-like growth factor binding protein-1 levels, 259, 260

- pathophysiology role, 256, 257
 - prospects for study, 262, 263
 - severe insulin resistance states, 259
- Interleukin-1 (IL-1)**
- insulin action effects, 56, 57
 - nutritional regulation of secretion and insulin-like growth factor-I expression effects, 33
 - protein metabolism effects, 54–56
- Interleukin-6 (IL-6)**
- nutritional regulation of secretion and insulin-like growth factor-I expression effects, 33
 - protein metabolism effects, 54–56
- Intestine, *see also* Inflammatory bowel disease**
- adaptation, 274, 282
 - insulin-like growth factor-I
 - binding protein modulation, 275, 276
 - developmental role, 140
 - mitogenic effects, 275
 - short bowel syndrome and resection
 - changes and therapy, 281–283
 - therapy in total parenteral nutrition, 278–280
 - transgenic mouse studies of
 - overexpression, 276, 277
 - transport improvement, 275
 - mucosal epithelial layer turnover, 272, 274
 - wall structure, 272
- IR, *see* Insulin receptor**
- J**
- Journals, listing for insulin-like growth factor research, 349–352**
- K**
- Kidney, insulin-like growth factor system, *see also* Renal failure**
- binding protein effects, 232
 - compensatory renal growth in failure, 237
 - diabetic nephropathy role, 236, 237
 - expression of components, 228–230
 - insulin-like growth factor-I effects
 - nephrogenesis, 230, 231
 - normal kidney structure and function, 231, 232
 - overview, 227
 - nephrotic syndrome, 237, 238
 - nutrition effects
 - metabolic acidosis, 234
 - potassium depletion, 233, 234
 - protein loading, 233
 - starvation and protein energy malnutrition, 233
 - prospects for study, 240
 - uptake and excretion of components, 230
- Knockout mouse**
- growth studies of insulin-like growth factor system
 - conditional insulin-like growth factor-I knockouts, 6, 7
 - postnatal growth, 124
 - prenatal growth, 124
 - insulin-like growth factor-I deletion effects, 6, 124, 141
 - insulin-like growth factor-II, 7, 124
 - insulin-like growth factor-I receptor, 124
 - mannose-6-phosphate/insulin-like growth factor-II receptor, 11
 - reproduction studies of insulin-like growth factor axis, 151, 152
- Knockout mouse, insulin-like growth factor system in glucose homeostasis, 254**
- L**
- Left ventricular hypertrophy, *see* Heart failure**
- LH, *see* Luteinizing hormone**
- Liver**
- disease and insulin-like growth factor-I in nutritional status assessment, 90
 - regulation of insulin-like growth factor-I expression, 5
- Luteinizing hormone (LH), critical illness and insulin-like growth factor system interactions, 303, 304**
- M**
- Malnutrition, *see also* Critical illness**
- assessment, *see* Nutritional status assessment
 - bone loss in protein malnutrition, 178–183
 - cytokine effects on protein metabolism, 54–56
 - insulin-like growth factor-I
 - expression effects, 26, 27, 35, 81
 - sensitivity effects, 38, 39
 - protein energy malnutrition
 - incidence, 76
 - insulin-like growth factor-I therapy in renal failure, 238, 239
 - types, 76, 77
 - renal effects, 233
 - stages, 77
- Manganese, insulin-like growth factor-I effects, 116**
- Mannose-6-phosphate/insulin-like growth factor-II receptor**
- functions, 11
 - tumor expression, 332
- Metabolic acidosis, renal effects, 234**

- MS, *see* Multiple sclerosis
- Multiple sclerosis (MS)
- impact on insulin-like growth factor system, 215
 - insulin-like growth factor-I therapy, 215
 - pathophysiology, 214, 215
- Muscle protein metabolism
- aging and insulin-like growth factor axis
 - defects in aging, 164
 - insulin-like growth factor-I regulation
 - catabolic conditions
 - alcohol ingestion, 200, 201
 - burns, 198–200
 - glucocorticoid excess, 201, 202
 - infection, 197, 198, 200
 - postsurgery, 200
 - skeletal muscle protein synthesis, 196, 197
 - whole-body protein metabolism, 194–196
 - insulin-like growth factor binding protein
 - effects, 202–205
 - overview of regulation, 193, 194, 205
 - prospects for study, 205
- Muscular dystrophy
- insulin-like growth factor-I therapy
 - prospects, 219
 - impact on insulin-like growth factor system, 219
- N**
- Nephrotic syndrome, insulin-like growth factor system, 237, 238
- Nutritional status assessment
- anthropometry, 80
 - biochemical markers, 77–80
 - body composition, 80
 - data in assessment, 77, 78
 - insulin-like growth factor-I as marker
 - anorexia nervosa, 88, 89
 - chronic nutritional status marker relationships
 - elderly, 163, 164
 - healthy adult studies, 85
 - infancy, 86
 - obesity, 86
 - puberty, 86
 - severe malnutrition, 86, 87
 - critical illness studies, 87, 88
 - cystic fibrosis, 90
 - limitations, 90, 91
 - liver disease, 90
 - overview of nutrient effects, 81, 82
 - prospects, 91, 92
 - renal failure, 89
 - repletion and monitoring of nutritional interventions, 82–85
 - standardization, 90, 91
 - undernourished children studies, 87
 - marker evaluation criteria, 77, 79
 - overview, 77
- O**
- Olivopontocerebellar atrophy, impact on insulin-like growth factor system, 214
- Omega-3 fatty acids, requirements in critical illness, 62, 63
- Osteoporosis
- insulin-like growth factor-I deficiency
 - and fracture risk, 179, 180
 - insulin-like growth factor axis defects
 - in aging, 164
 - protein intake relationship with bone mineral density
 - animal studies, 181, 182
 - elderly, 178–181
 - mechanisms, 182, 183
 - young adults, 183, 184
- Ovary, insulin-like growth factor axis, 146, 147
- Oviduct, insulin-like growth factor axis, 147, 148
- P**
- Parathyroid hormone (PTH), regulation of insulin-like growth factor-I expression, 5
- Parkinson's disease (PD), insulin-like growth factor-I therapy prospects, 213
- PD, *see* Parkinson's disease
- Perinatal insulin-like growth factor axis
- nutrition effects on action, 139
 - overview, 136
- Phosphorous, metabolism in bone growth, 184, 185
- Postnatal insulin-like growth factor axis, 136
- Potassium, depletion effects on kidney, 233, 234
- pp120, insulin receptor modulation, 12, 13
- Professional societies and organizations, 345–238
- Prostaglandin E2
- regulation of insulin-like growth factor-I expression, 5
- Prostate cancer, *see* Cancer
- Protein energy malnutrition, *see* Malnutrition
- Protein metabolism, *see* Muscle protein metabolism
- PTH, *see* Parathyroid hormone
- Pygmies, insulin-like growth factor system
 - defects, 125
- R**
- Renal failure
- insulin-like growth factor-I
 - nutritional status assessment, 89
 - therapy
 - acute renal failure, 239
 - chronic renal failure, 239

- growth retardation, 239
- protein energy malnutrition, 238, 239
- insulin-like growth factor system
 - effects, 234, 235
 - progression role, 238
- Reproduction, insulin-like growth factor axis
 - circulating system, 150, 151
 - nutrition interactions, 145, 146
 - ovary, 146, 147
 - oviduct, 147, 148
 - prospects for study, 152
 - testes, 150
 - transgenic and knockout mouse studies, 151, 152
 - uterus, 148–150
- Retinopathy of prematurity (ROP), insulin-like growth factor axis defects, 140
- Review literature, insulin-like growth factors, 343
- ROP, *see* Retinopathy of prematurity
- S**
- Short bowel syndrome
 - indications for resection, 281
 - insulin-like growth factor system
 - in adaptation, 282
 - insulin-like growth factor-I therapy, 282, 283
 - parenteral nutrition, 281, 282
- Small intestine, *see* Intestine
- Snell mouse, longevity, 166
- Steroid myopathy, impact on insulin-like growth factor system, 219
- T**
- Telomerase, insulin-like growth factor-I effects on activity, 165
- Testes, insulin-like growth factor axis, 150
- Testosterone, therapy in critical illness, 64
- TGF- α , *see* Tumor necrosis factor- α
- Thyroid hormone
 - critical illness and insulin-like growth factor system interactions, 301, 303, 304
 - nutritional regulation of secretion and insulin-like growth factor-I expression effects, 31, 32
- Thyroid-stimulating hormone (TSH), regulation of insulin-like growth factor-I expression, 5
- Total parenteral nutrition (TPN)
 - animal models, 278
 - growth hormone therapy, 280, 281
 - indications, 277, 278
 - insulin-like growth factor-I therapy, 278–280
- TPN, *see* Total parenteral nutrition
- Traumatic brain injury, insulin-like growth factor-I therapy prospects, 218, 219
- TSH, *see* Thyroid-stimulating hormone
- Tumor necrosis factor- α (TGF- α)
 - bone loss role in protein malnutrition, 182, 183
 - insulin action effects, 56, 57
 - insulin-like growth factor-I action effects, 57, 58
 - muscle protein effects, 200
 - nutritional regulation of secretion and insulin-like growth factor-I expression effects, 33
 - protein metabolism effects, 54–56
- U**
- Ulcerative colitis, *see* Inflammatory bowel disease
- Uterus, insulin-like growth factor axis, 148
- Z**
- Zinc
 - deficiency
 - growth hormone response
 - expression, 108–110
 - sensitivity, 110
 - growth inhibition, 107, 108
 - insulin-like growth factor-I response
 - expression, 108–110
 - sensitivity, 110
 - effects on insulin-like growth factor-I and growth hormone homeostasis, 112, 113
 - homeostasis and insulin-like growth factor-I or growth hormone effects, 112
 - prospects for growth studies, 117
 - signal transduction in growth pathways, 113–117
 - supplementation studies with insulin-like growth factor-I or growth hormone therapy, 111